Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy

Burzynski, Stanislaw R.; Janicki, Tomasz; Burzynski, Gregory S.

doi:10.5539/cco.v4n2p41

Cited by 9 publications

(8 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven brain tumor cases from Phase I and II studies (including BT-3) were reviewed on October 4, 1991 by three members of the NIH Cancer Therapy Evaluation Program, an invited neuropathologist, and an invited neuroradiologist. Five definite or "possible" complete responses (CRs) were identified [30].…”

Section: Discussionmentioning

confidence: 99%

A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons

Burzynski¹,

Burzynski²,

Janicki³

et al. 2022

IJCOCR

View full text Add to dashboard Cite

Rationale: Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumorrelated death in children. Over the past few decades, clinical trials have shown no improvement in outcome. Most DIPGs occur in the pediatric population. Adult brainstem gliomas are rare, constitute less than 2% of adult gliomas, and show a slight male predominance. The case of this 25-year-old female is presented to detail and discuss the use of Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) in the treatment of DIPG that persisted despite radiation therapy (RT) and temozolomide. Objectives: The patient described was treated at the Burzynski Clinic (BC), as a special exception, according to the phase II protocol, BT-09, which utilized Antineoplastons A10 and AS2-1 (ANP therapy) in the treatment of brain tumors. The delivery of ANP therapy was via a subclavian catheter and infusion pump. Tumor response to therapy was measured by sequential magnetic resonance imaging (MRI) of the brain. Overall Survival (OS) and Adverse Events (AES) were also documented. Findings: At her presentation to the BC, the patient complained of diplopia, left-sided weakness, and difficulty walking. On physical exam, she was alert and orientated. Her cranial nerves were intact. There was weakness of the left-sided extremities. Deep tendon reflexes were equal bilaterally with down-going toes bilaterally. Reports of the original brain MRIs in Argentina suggested a DIPG with extension to the medulla and cerebellum. In addition, tumor biopsy confirmed a grade 3 astrocytoma. Following radiation therapy (RT) and temozolomide in Argentina, the patient was treated at BC for persistent disease with ANP therapy. Sequential MRI imaging of the residual tumor, which was non-enhancing, showed no change in size during therapy. However, the patient did achieve resolution of her neurologic signs and symptoms and has survived more than nine years since first being seen at BC. Correspondence with the patient on September 9, 2021 indicated she was feeling fine, had a healthy child, and was enjoying life. Conclusions: We have presented here the case of an adult female with a DIPG who had resolution of signs and symptoms and survived more than nine years after ANP therapy. For patients with DIPG (or other highgrade astrocytoma), who do not qualify for/refuse RT or show persistent or progressive disease following RT and/or chemotherapy, ANP therapy is an effective therapeutic option. In collaboration with the FDA confirmatory Phase II and Phase III studies have been developed.

show abstract

Section: Discussionmentioning

confidence: 99%

A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons

Burzynski¹,

Burzynski²,

Janicki³

et al. 2022

IJCOCR

View full text Add to dashboard Cite

show abstract

“…In cancer, alteration of these control genes in malignant cells favors aggressive cell proliferation. Evidence suggests that ANP therapy affects 112 genes in the GBM genome and functions as "molecular switches" which "turn on" tumor-suppressor genes and "turn off " oncogenes [27,28]. Hence, the antineoplastic action of ANP therapy in DIPG involves restoration of cell cycle control, induction of programmed cell death, and interference with cancer cell metabolism and nuclear transport.…”

Section: Discussionmentioning

confidence: 99%

Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-free Survival in a 45-Year-Old Female Treated with Antineoplastons (Successful Treatment of Glioblastoma with Antineoplastons)

2022

Cancer Stud Ther J

View full text Add to dashboard Cite

metabolic processes, such as the Krebs cycle, glutamine metabolism, lipogenesis and redox regulation [8][9][10]. Concerning the diagnosis of GBM, the 2016 revision of the World Health Organization (WHO) of CNS tumors, included IDH status, which resulted in three sub-groups, IDH-wild-type, IDH-mutant, and not otherwise specified (NOS) [11,12]. IDH-wild-type GBM is characterized by de novo development with no identifiable precursor lesion and represents 90% of patients with GBM [12]. On the other hand, IDH-mutant GBM, typically arises from a precursor diffuse or anaplastic astrocytoma and represents 10% of patients with GBM [12]. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is seen in 30-50% of IDH-wild-type GBMs and may allow a better response to alkylating chemotherapy, especially temozolomide, providing for a better prognosis [13].Gadolinium-enhanced magnetic resonance imaging (MRI) of the brain is used in the diagnosis and follow-up of GBM. T2-weighted, T2-fluid attenuated inversion recovery (T2-FLAIR), T1 weighted, and T1-weighted contrast-enhanced images are obtained. GBMs are gadolinium-enhancing and sequential T1-weighted contrastenhanced images are utilized to determine the effect of therapy [14,15].

show abstract

“…In cancer, alteration of these control genes in malignant cells favors aggressive cell proliferation. Evidence suggests that ANP therapy affects 204 mutated genes in the malignant genome and functions as a "molecular switch" which "turns on" tumor-suppressor genes and "turns off" oncogenes [25,26]. Hence, the antineoplastic action of ANP therapy in GBM involves restoration of cell cycle control, induction of programmed cell death, and interference with cancer cell metabolism and nuclear transport.…”

Section: Discussionmentioning

confidence: 99%

Newly Diagnosed Glioblastoma: Partial Response and > 27 Years Overall Survival in 37-Year-Old Male Treated with Antineoplastons (Treatment of Glioblastoma with Antineoplastons)

Burzyński¹,

Gregory²,

Janicki³

et al. 2022

Recent Adv Clin Trials

View full text Add to dashboard Cite

Glioblastoma (GBM), with its very poor prognosis, accounts for 57% of gliomas and 48% of malignant central nervous system (CNS) tumors. After standard therapy, patients with GBM usually die within six months. The case of an adult male with a newly-diagnosed GBM is presented here to detail/discuss the efficacy of ANP therapy (Antineoplaston A10 {Atengenal} and Antineoplaston AS2-1 {Astugenal}) in the treatment of GBM and to permit a review of the Phase II Protocol BT-07. Objectives: This patient was treated at the Burzynski Clinic (BC), according to the Phase II Protocol, BT-07, which utilized IV ANP therapy in the treatment of patients with newly-diagnosed GBMs. ANP therapy was delivered via subclavian catheter and infusion pump. Tumor response was measured by sequential magnetic resonance imaging (MRI) of the brain utilizing gadolinium enhancement. Findings: At age 37, this patient was diagnosed with GBM of the right frontal lobe after subtotal tumor resection performed elsewhere. At age 37 years and six months, he presented to the BC with this newly diagnosed disease. He had a recent history of forgetfulness and personality change. Neurologic examination was otherwise normal. Baseline brain MRI at the BC revealed a measurable enhancing nodule (4.0 cm x 2.0 cm) in the right frontal lobe. Intravenous (IV) ANP therapy began in November 1995 and a partial response (PR) was achieved within three months. After another 5 months of IV ANP therapy, the patient underwent a complete tumor resection, then additional ANP therapy. Now, > 27 years later, the patient is doing well and showing no evidence of tumor recurrence. Conclusions: The utilization of ANP therapy to facilitate a cure in a patient with newly-diagnosed GBM is presented. We conclude that ANP therapy is an attractive therapeutic option for adults with a GBM who are ineligible for or refuse standard therapy.

show abstract

Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy

Cited by 9 publications

References 70 publications

A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons

A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons

Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-free Survival in a 45-Year-Old Female Treated with Antineoplastons (Successful Treatment of Glioblastoma with Antineoplastons)

Newly Diagnosed Glioblastoma: Partial Response and > 27 Years Overall Survival in 37-Year-Old Male Treated with Antineoplastons (Treatment of Glioblastoma with Antineoplastons)

Contact Info

Product

Resources

About